Lynbrook Pharmaceutical Company May Have Cure for Penis Curvature

may have played a major role in curing a rather embarrassing men's disease.

The bio-pharmaceutical company, based out of Lynbrook, was first to develop the drug Xiaflex, which aims at curing Peyronie's disease.

According to Peyronies.org, "Men with Peyronie's disease generally seek medical attention for pain or bending of the penis during erection, which results from inflammation and scarring in a particular part of the male anatomy known as the tunica albuginea."

Results from the two randomized, double-blind, placebo-controlled studies at 52 weeks demonstrated statistically significant improvements in both co-primary endpoints of the trials, including percent improvement from baseline in penile curvature deformity compared to placebo and change from baseline (improvement) in the Peyronie's disease bother domain of Auxilium's Peyronie's Disease Questionnaire (PDQ) compared to placebo, according to a release.

Said President of BioSpecifics Thomas L. Wegman:

"We are very pleased with these positive top-line Phase III results and are enthusiastic about the potential availability of XIAFLEX as the first FDA-approved prescription product labeled for treatment of Peyronie's disease that could be administered in a physician's office. Peyronie's disease can be psychologically devastating for patients and the only proven therapy available today is penile surgery."

FoxBusiness reported Monday that Auxilium Pharmaceuticals, which helped develop and market the drug, saw a nearly 10 percent climb in shares after the positive results were announced.

According to the New York Times, BioSpecifics earns royalties on the sales of Xiaflex.